New 'Genesis' for Viragen's Anti-CD55 Cancer Program
By Jennifer Boggs
Friday, December 17, 2010
Failed biotech Viragen Inc. might have called it quits in 2007, but its monoclonal antibody targeting CD55 was reborn in start-up Genesis Biopharma Inc., which licensed the CD55-related assets earlier this year and plans to move forward with testing in both solid tumors and blood cancers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.